Milestone Pharmaceuticals Inc. Quarterly Debt-to-equity in % from Q3 2019 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Milestone Pharmaceuticals Inc. quarterly Debt-to-equity history and growth rate from Q3 2019 to Q2 2024.
  • Milestone Pharmaceuticals Inc. Debt-to-equity for the quarter ending June 30, 2024 was 197 %, a 258% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 197 +142 +258% Jun 30, 2024
Q1 2024 183 +155 +562% Mar 31, 2024
Q4 2023 165 +157 +1970% Dec 31, 2023
Q3 2023 95.4 +88.6 +1309% Sep 30, 2023
Q2 2023 54.9 +49.4 +907% Jun 30, 2023
Q1 2023 27.6 +22.5 +441% Mar 31, 2023
Q4 2022 7.99 +2.91 +57.3% Dec 31, 2022
Q3 2022 6.77 +2.06 +43.7% Sep 30, 2022
Q2 2022 5.45 +0.46 +9.21% Jun 30, 2022
Q1 2022 5.11 -0.27 -5.02% Mar 31, 2022
Q4 2021 5.07 -0.49 -8.8% Dec 31, 2021
Q3 2021 4.72 -1.65 -25.9% Sep 30, 2021
Q2 2021 4.99 -1.49 -23% Jun 30, 2021
Q1 2021 5.38 -0.63 -10.5% Mar 31, 2021
Q4 2020 5.57 -0.51 -8.39% Dec 31, 2020
Q3 2020 6.36 +0.76 +13.6% Sep 30, 2020
Q2 2020 6.48 Jun 30, 2020
Q1 2020 6.01 Mar 31, 2020
Q4 2019 6.08 Dec 31, 2019
Q3 2019 5.6 Sep 30, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.